Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Euronext N.V.. (2/2/17). "Press Release: Euronext and Biotech Bourse Launch First Quarterly Barometer for Biotech Sector". Amsterdam, et al..

Organisations Organisation Euronext N.V.
  Group Euronext (Group)
  Organisation 2 – Sacha Pouget (Biotech Bourse)
Products Product Biotech Barometer (Baromètre Biotech) (Euronext / Biotech Bourse)
  Product 2 BIOTECH

> The “Biotech Barometer" highlights listed biotech companies

> A quarterly review designed to identify market trends

> Barometer reveals renewed interest in biotech stocks despite cautious market segment in Q4 2016

Euronext today published its first “Biotech Barometer”, a new quarterly tool that offers an insight into major trends in biotechnology companies[1] listed on Euronext markets. Designed in partnership with Biotech Bourse, the barometer shows performance indicators, investor interest and market sentiment specifically for this sector.

Highlighting biotech

Biotech is a key sector for Euronext: between 2012 and 2016 the number of biotech companies listed on its markets rose from 12 to 45, with a market capitalisation of nearly €12 billion. The Biotech Barometer is designed to showcase this fast-moving sector. In addition to providing information to biotech companies—both listed and unlisted—it will help CEOs assess their momentum against a broader benchmark and give ordinary investors a simple guide to tracking market trends.

The quarterly publication is underpinned by data and innovative tools developed by Biotech Bourse and Euronext’s Post-Listing Services. The Biotech Barometer includes:

> Trends in market statistics—prices, volumes and indexes

> A market sentiment indicator

> Institutional investor interest (number, capital invested, region of origin)

> Key performance indicators for the biotech industry: companies’ cash positions, calls on the market, treatment areas and published clinical results.

Key findings of first Biotech Barometer

Although market sentiment remained cautious, Euronext and Biotech Bourse found that interest in biotech stocks rallied in Q4 2016. Specific findings:

> Trading volumes rose. December was the sector’s fourth best month in 2016: trading in the 45 Euronext-listed biotech stocks covered by the Barometer generated over €46 million daily.

> Some 140 new institutional investors bought shares in the 45 biotech companies, producing capital inflows of over €600 million. While 75% of these investors were based in Europe, 20% were in North America and 5% were in Asia.

> The rate of calls on the market increased: the 45 Biotech companies listed on Euronext markets raised €214 million in Q4, up 75.2% over the previous quarter. In total they raised over €1 billion in 2016 (primary and secondary issues combined)

> At year-end 2016, some 330 institutional investors were identified as holding positions in the 45 biotech companies, with combined holdings of over €3 billion and two-thirds of that total from Europe.

To browse Biotech Barometer, visit Euronext Tech Corner. Join the conversation on social media using the hashtag #BiotechBarometer.

[1] Includes only companies offering diagnostics and therapies

About Euronext

Euronext is the leading pan-European exchange in the Eurozone with more than 1 300 listed issuers worth close to €3.3 trillion in market capitalization as of end December 2016, an unmatched blue chip franchise consisting of 25 issuers in the EURO STOXX 50® benchmark and a strong diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs’ access to capital markets.

For the latest news, find us on Twitter ( and LinkedIn (


This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2017, Euronext N.V. - All rights reserved.

Contact details

Chief Communications Officer
Pauline Bucaille
Tel: +33 (0)1 70 48 24 41

Alice Jentink
Tel: +31 (0) 20 721 4488

Pascal Brabant
Tel: +32 2 620 15 50

Sandra Machado
Tel: +351 210 600 614

Aichata Tandjigora
Tel: +33 (0)1 70 48 24 43

Record changed: 2023-06-05


Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x200px

More documents for Euronext (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top